Raymond James & Associates’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-24,745
Closed -$250K 3937
2022
Q4
$250K Sell
24,745
-2,239
-8% -$42K ﹤0.01% 3323
2022
Q3
$605K Sell
26,984
-2,831
-9% -$81.8K ﹤0.01% 2734
2022
Q2
$739K Buy
29,815
+379
+1% +$10.5K ﹤0.01% 2651
2022
Q1
$1.14M Buy
29,436
+8,790
+43% +$340K ﹤0.01% 2496
2021
Q4
$1.21M Buy
20,646
+250
+1% +$14.2K ﹤0.01% 2497
2021
Q3
$1.21M Buy
20,396
+355
+2% +$27.8K ﹤0.01% 2450
2021
Q2
$1.74M Buy
20,041
+16
+0.1% +$1.29K ﹤0.01% 2193
2021
Q1
$1.65M Sell
20,025
-2,934
-13% -$281K ﹤0.01% 2148
2020
Q4
$2.09M Buy
22,959
+2,534
+12% +$157K ﹤0.01% 1868
2020
Q3
$816K Sell
20,425
-925
-4% -$32.3K ﹤0.01% 2301
2020
Q2
$733K Sell
21,350
-900
-4% -$26.8K ﹤0.01% 2346
2020
Q1
$494K Sell
22,250
-11,997
-35% -$303K ﹤0.01% 2426
2019
Q4
$670K Sell
34,247
-6,210
-15% -$98.6K ﹤0.01% 2526
2019
Q3
$628K Buy
40,457
+5,819
+17% +$112K ﹤0.01% 2501
2019
Q2
$703K Buy
34,638
+2,090
+6% +$37.7K ﹤0.01% 2430
2019
Q1
$572K Buy
32,548
+5,110
+19% +$80.7K ﹤0.01% 2563
2018
Q4
$352K Sell
27,438
-1,850
-6% -$25.8K ﹤0.01% 2770
2018
Q3
$477K Buy
29,288
+2,085
+8% +$24.7K ﹤0.01% 2741
2018
Q2
$308K Buy
27,203
+453
+2% +$4.99K ﹤0.01% 3006
2018
Q1
$261K Buy
26,750
+3,725
+16% +$35.7K ﹤0.01% 2978
2017
Q4
$141K Buy
+23,025
New +$103K ﹤0.01% 3149

Other funds holding FATE